Evaxion AS (EVAX)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

The new data demonstrates the potential to improve control of acute infection, latency, and viral reactivation...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop

New preclinical data will guide antigen selection for a broadly protective cytomegalovirus vaccine...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Evaxion receives Prix Galien UK Award for Best digital health solution

COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia

EVX-04 is successfully expressed and secreted in human cells enabling immune recognition and activationThe...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress

Data will reflect the functional characterization of EVX-04Poster presentation on June 13, 2026 COPENHAGEN...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Evaxion announces business update and first quarter 2026 financial results

COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026

COPENHAGEN, Denmark, May 4, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]